Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Clinical trial NCT02038036 · COMPLETED
Trial details
- NCT number
- NCT02038036
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-25
- Primary completion
- 2015-09-29
- Enrollment
- 149
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.